Clinical Assistant Professor
Medical Director, VGH Diabetes Centre
University of San Diego, 1985, Endocrinology Fellowship

1: Atkins PW, Thompson DM. Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis. Diabetes Metab. 2018 Dec;44(6):514-515.

2: Clement M, Paty B, Mancini J, Miller D, Mudaliar A, Shu D, Thompson D, White A, Ur E. Challenges to managing type 2 diabetes in British Columbia: Discordant guidelines and limited treatment options. BCMJ 2018 Nov; 60(9): 439-450.

3: Fensom B, Harris C, Thompson SE, Al Mehthel M, Thompson DM. Islet cell transplantation improves nerve conduction velocity in type 1 diabetes compared with intensive medical therapy over six years. Diabetes Res Clin Pract. 2016 Dec;122:101-105.

4: Kong JM, Lim K, Thompson DM. Evaluation of the International Association of the Diabetes In Pregnancy Study Group new criteria: gestational diabetes project. Can J Diabetes. 2015 Apr;39(2):128-32..

5: Park YJ, Ao Z, Kieffer TJ, Chen H, Safikhan N, Thompson DM, Meloche M, Warnock GL, Marzban L. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia. 2013 Mar;56(3):508-19.

6: Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, Ho S, Worsley D, Fung M, Meneilly G, Begg I, Al Mehthel M, Kondi J, Harris C, Fensom B, Kozak SE,  Tong SO, Trinh M, Warnock GL. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011 Feb 15;91(3):373-8.

Gordon and Leslie Diamond Centre 4th Floor
2775 Laurel St.
Vancouver, BC V5Z 1M9
phone: 6048755919